Archived Press Releases

Cardioxyl Pharmaceuticals Presents Data on its Clinical Candidate, CXL-1020, at the 60th Annual American College of Cardiology Scientific Session

Cardioxyl Pharmaceuticals Initiates Dose-Defining Phase IIA Study of Its Lead Candidate, CXL-1020, in Heart Failure Patients

Cardioxyl Pharmaceuticals Announces Positive Results from First Clinical Study of it's Lead Therapy, CXL-1020, in Heart Failure Patients

Cardioxyl Raises $14.5MM Series A Financing

Nitroxyl Technology

Cardioxyl has developed proprietary expertise in the biology, physiology and chemistry of nitroxyl donors

Our Mission

Cardioxyl's mission is to realize the potential of nitroxyl technology through the development of novel therapies that improve the health and quality of life of patients with serious cardiovascular disease.